![Alan Barge](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alan Barge
Directeur/Membre du Conseil chez
THERACRYF PLC
Profil
Alan Barge was the founder of ASLAN Pharmaceuticals Pte Ltd., founded in 2016, where the title held was Senior Vice President-Oncology.
Current jobs include Chief Executive Officer at Tilikum Therapeutics, Inc. since 2023; Director at West Thorpe (2011) Ltd.; Director & Investor Director at Oribiotech Ltd.; Senior Independent Non-executive Director at TheraCryf Plc since 2024; and Venture Partner at Delin Ventures Ltd. since 2019.
Former jobs include Chairman-Supervisory Board at Modra Pharmaceuticals BV; Global Medical Director-European at Amgen, Inc. from 1990 to 1998; Vice President-Clinical & Head-Oncology at AstraZeneca PLC from 2009 to 2010; and Chief Medical Officer at Oncoinvent ASA from 2018 to 2019.
Education includes graduation from the University of Oxford in 1983.
Postes actifs de Alan Barge
| Sociétés | Poste | Début |
|---|---|---|
| THERACRYF PLC | Directeur/Membre du Conseil | 14/10/2015 |
West Thorpe (2011) Ltd. | Directeur/Membre du Conseil | - |
Oribiotech Ltd.
 Oribiotech Ltd. BiotechnologyHealth Technology Develops and manufactures cell and gene therapy | Directeur en chef des Investissements | - |
Delin Ventures Ltd.
 Delin Ventures Ltd. Investment ManagersFinance Delin Ventures invests in companies located in Europe, primarily in the United Kingdom, Germany, Austria, and Switzerland. The firm targets companies operating in the fields of life sciences and manufacturing technologies sectors. It provides financing for pre-seed, seed and early stage capital requirements with an investment size of EUR 0.5 - 2 million. | Private Equity Investor | 01/03/2019 |
Tilikum Therapeutics
 Tilikum Therapeutics Hospital/Nursing ManagementHealth Services Provides cancer treatment services | Directeur Général | 01/01/2023 |
Anciens postes connus de Alan Barge
| Sociétés | Poste | Fin |
|---|---|---|
| ONCOINVENT ASA | Directeur Technique/Scientifique/R&D | 13/03/2019 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/12/2010 |
| AMGEN INC. | Corporate Officer/Principal | 01/09/1998 |
Modra Pharmaceuticals BV
 Modra Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Designs and develops oral formulations of commonly used anti-cancer drugs | Président | - |
| ░░░░░ ░░░░░░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░ | - |
Formation de Alan Barge
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
79
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Evgen Pharma Plc
 Evgen Pharma Plc Medical/Nursing ServicesHealth Services Engages in the development of pharmaceutical products and focus on cancer & neurological disease | Health Services |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BerGenBio ASA
 BerGenBio ASA Pharmaceuticals: MajorHealth Technology Develops drugs for aggressive, drug resistant cancers | Health Technology |
ASLAN Pharmaceuticals Pte Ltd.
 ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology Develops novel medicines for global markets | Health Technology |
West Thorpe (2011) Ltd. | |
Modra Pharmaceuticals BV
Modra Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Designs and develops oral formulations of commonly used anti-cancer drugs | Health Technology |
Delin Ventures Ltd.
Delin Ventures Ltd. Investment ManagersFinance Delin Ventures invests in companies located in Europe, primarily in the United Kingdom, Germany, Austria, and Switzerland. The firm targets companies operating in the fields of life sciences and manufacturing technologies sectors. It provides financing for pre-seed, seed and early stage capital requirements with an investment size of EUR 0.5 - 2 million. | Finance |
Oribiotech Ltd.
Oribiotech Ltd. BiotechnologyHealth Technology Develops and manufactures cell and gene therapy | Health Technology |
Tilikum Therapeutics
Tilikum Therapeutics Hospital/Nursing ManagementHealth Services Provides cancer treatment services | Health Services |
Choisissez Zonebourse 
